CMH :: Clinical and Molecular Hepatology

REVIEW Life-sustaining treatment and palliative care in patients with liver cirrhosis - legal, ethical, and practical issues
With the enactment of the ‘Act on Decisions on Life-Sustaining Treatment for Patients in Hospice and Palliative Care or at the End of Life’ (Act No. 14013) in Korea, there is growing concern about the practicality of this law. In this review, we discuss definitions, ethics, a...

ORIGINAL ARTICLE A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
Background/Aims: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular c...

ORIGINAL ARTICLE Meta-analysis of the correlation between the rs17401966 polymorphism in kinesin family member 1B and susceptibility to hepatitis B virus related hepatocellular carcinoma
Background/Aims: The association between the kinesin family member 1B (KIF1B) gene polymorphism and the risk of hepatitis B virus-related hepatocellular carcinoma (HCC) has been investigated in many peer-reviewed studies. However, scholars have failed to replicate these results ...

Current Issue

Volume 23(2); Jun 2017

Volume 23(1); March 2017

Volume 22(4); December 2016

Volume 22(3); September 2016

Volume 22(2); June 2016

Most-cited are based on citations from 2015 ~ 2017.

A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016

Su Jong Yu

Clin Mol Hepatol.2016;22(1):7-17. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.7

Cited By 21

KASL clinical practice guidelines: management of chronic hepatitis B

Clin Mol Hepatol.2016;22(1):18-75. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.18

Cited By 20

Hepatitis C virus-induced hepatocellular carcinoma

Nicolas Goossens, Yujin Hoshida

Clin Mol Hepatol.2015;21(2):105-114. Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.105

Cited By 19

Personalized management of cirrhosis by non-invasive tests of liver fibrosis

Grace Lai-Hung Wong, Wendell Zaragoza Espinosa, Vicnent Wai-Sun Wong

Clin Mol Hepatol.2015;21(3):200-211. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.200

Cited By 12

The mutational landscape of hepatocellular carcinoma

Ju-Seog Lee

Clin Mol Hepatol.2015;21(3):220-229. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.220

Cited By 12

Clinical implications of advances in liver regeneration

Yong Jin Kwon, Kyeong Geun Lee, Dongho Choi

Clin Mol Hepatol.2015;21(1):7-13. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.7

Cited By 12

Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis

Yoon Ok Jang, Baek Gyu Jun, Soon Koo Baik, Moon Young Kim, Sang Ok Kwon

Clin Mol Hepatol.2015;21(2):141-149. Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.141

Cited By 9

The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B

In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim

Clin Mol Hepatol.2015;21(1):32-40. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.32

Cited By 9

Personalized treatment of hepatitis B

Anna S. Lok

Clin Mol Hepatol.2015;21(1):1-6. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.1

Cited By 8

New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis

Hyun Young Woo, Jeong Heo

Clin Mol Hepatol.2015;21(2):115-121. Published online June 26, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.2.115

Cited By 7

Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase

Yasuko Iwakiri

Clin Mol Hepatol.2015;21(4):319-325. Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.319

Cited By 6

The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease

Goh Eun Chung, Donghee Kim, Min-Sun Kwak, Jong In Yang, Jeong Yoon Yim, Seon Hee Lim, Mustafa Itani

Clin Mol Hepatol.2016;22(1):146-151. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.146

Cited By 6

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir

Han Na Choi, Jeong Eun Song, Hyeon Chul Lee, Hyeong Ho Jo, Chang Hyeong Lee, Byung Seok Kim

Clin Mol Hepatol.2015;21(1):24-31. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.24

Cited By 5

Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease

Chansik An, Youn Ah Choi, Dongil Choi, Yong Han Paik, Sang Hoon Ahn, Myeong-Jin Kim, Seung Woon Paik, Kwang-Hyub Han, Mi-Suk Park

Clin Mol Hepatol.2015;21(3):279-286. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.279

Cited By 5

Imaging findings of mimickers of hepatocellular carcinoma

Tae Kyoung Kim, Eunchae Lee, Hyun-Jung Jang

Clin Mol Hepatol.2015;21(4):326-343. Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.326

Cited By 5

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients

Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa

Clin Mol Hepatol.2015;21(1):41-48. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.41

Cited By 5

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

Ha Ra Gu, Su Cheol Park, Su Jin Choi, Jae Cheol Lee, You Cheoul Kim, Chul Ju Han, Jin Kim, Ki Young Yang, Yeon Joo Kim, Geum Youb Noh, So Hyeon No, Jae-Hoon Jeong

Clin Mol Hepatol.2015;21(1):49-59. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.49

Cited By 5

KASL clinical practice guidelines: management of hepatitis C

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol.2016;22(1):76-139. Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.76

Cited By 5

Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

Jung Gil Park

Clin Mol Hepatol.2015;21(3):287-294. Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.287

Cited By 4

Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient

Jin Ok Kim, Dae Won Jun, Hye Jin Tae, Kang Nyeong Lee, Hang Lak Lee, Oh Young Lee, Ho Soon Choi, Byung Chul Yoon, Joon Soo Hahm

Clin Mol Hepatol.2015;21(1):85-88. Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.85

Cited By 4

The Korean Association for the Study of the Liver